• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    2 Things Relay Therapeutics (RLAY) Results Say About Its 4.9x P B Valuation

    Simply Wall St·08/09/2026 21:31:02
    Listen to the news

    Relay Therapeutics earnings update and what it might mean for the stock

    Relay Therapeutics (RLAY) reported second quarter 2026 results today, with lower revenue and a wider net loss compared with a year earlier. These figures provide a fresh snapshot of the company’s progress and cash burn.

    See our latest analysis for Relay Therapeutics.

    Relay Therapeutics shares have pulled back slightly over the past month, with a 30 day share price return of 1.17% lower. However, momentum has been strong this year, with a 90 day share price return of 53.85% and a year to date share price return of 141.69%. The recent earnings release, including a wider loss, sits against a very large 1 year total shareholder return of more than 5x and an 84.25% total shareholder return over 3 years. This suggests investors have already reacted strongly to shifting expectations around the company’s prospects and risk profile.

    If Relay Therapeutics has you thinking about other healthcare opportunities that blend treatment with data and computation, it may be worth reviewing a focused list of 43 healthcare AI stocks.

    Relay Therapeutics now trades well below the average analyst price target after a huge 1 year run and a wider recent loss. Is that discount a margin of safety, or a sign the market’s caution is justified?

    Preferred price to book of 4.9x for Relay Therapeutics: Is it justified?

    Relay Therapeutics closed at $19.77, and on a P/B of 4.9x it sits in an interesting spot compared with both its direct peers and the wider US biotechs industry. The stock has delivered a very large 1 year total return, so this valuation ratio is an important check on how much optimism is already reflected in the share price.

    The P/B multiple compares a company’s market value with its accounting book value. For a clinical stage biotech like Relay Therapeutics that is still loss making, this is often used in place of a P/E ratio because earnings are negative and do not yet provide a meaningful yardstick. A higher P/B can reflect expectations for future revenue growth, the perceived quality of a pipeline, or confidence in management and governance.

    According to Simply Wall St’s data, Relay Therapeutics trades on a P/B of 4.9x. That is well below a peer average of 24.2x, which points to a lower valuation than some similar companies when simply comparing market value to book value. At the same time, the stock is described as expensive relative to the broader US biotechs industry average P/B of 2.5x, which suggests the market is still assigning a premium to its platform, pipeline and forecast revenue growth despite ongoing losses.

    This split picture matters for investors trying to frame expectations. On one hand, Relay Therapeutics does not carry the very high P/B multiple seen in some peer companies. On the other, it is priced at almost double the wider industry average, and analysts expect revenue to grow faster than both the US market and the sector overall. That combination can leave less room for disappointment if execution or capital needs do not line up neatly with those forecasts.

    For a closer look at how this P/B compares with other ways of thinking about valuation, and how that might shift as the story develops, See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 4.9x (ABOUT RIGHT)

    However, Relay Therapeutics still faces clinical and regulatory uncertainty, and its current net loss of $286.037 million means funding and dilution risks remain firmly on the table.

    Find out about the key risks to this Relay Therapeutics narrative.

    Next Steps

    With Relay Therapeutics showing both clear risks and some potential rewards, now is a good time to review the details and decide where you stand. To see the full picture of concerns and upsides in one place, take a closer look at the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Relay Therapeutics?

    If Relay Therapeutics has sharpened your interest in high conviction opportunities, do not stop here. The next smart move is widening your watchlist with focused screeners that surface ideas you might otherwise miss.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.